Back to results
US 12,240,883 B2Granted
MAGEA1 specific T cell receptors and their use
AssigneeMedigene Immunotherapies GmbH
InventorsCarina Wehner, Manon Weis, Silke Raffegerst, Anja Mösch
Life of this patent
Estimating the term…
Abstract
The present invention relates to an isolated T cell receptor (TCR) specific for a MAGEA1-derived peptide and to a polypeptide comprising a functional portion of the TCR. Further implicated are a multivalent TCR complex, a nucleic acid encoding a TCR, a cell expressing the TCR and a pharmaceutical composition comprising the TCR. The invention also refers to the TCR for use as a medicament, in particular to the TCR for use in the treatment of cancer.
Claims9
An isolated T cell receptor (TCR) specific for Melanoma-Associated Antigen 1 (MAGEA1), wherein the TCR comprises
- a TCR α chain comprising
- a CDR1 having the amino acid sequence of SEQ ID NO:
- 2,
- a CDR2 having the amino acid sequence of SEQ ID NO:
- 3 and
- a CDR3 having the amino acid sequence of SEQ ID NO:
- 4;
- and
- a TCR β chain comprising
- a CDR1 having the amino acid sequence of SEQ ID NO:
- 5,
- a CDR2 having the amino acid sequence of SEQ ID NO:
- 6 and
- a CDR3 having the amino acid sequence of SEQ ID NO:
- 7.
12 more elements
Dependencies are inferred from the claim text.